Description

Simple

Clinical

Overview

XTL001 is an investigational monoclonal antibody (MAb) product developed by XTL Biopharmaceuticals to evaluate the safety profile and antiviral activity of the compound in patients chronically infected with hepatitis B virus (HBV).

Pharmacology

Indication

Investigated for use/treatment in hepatitis (viral, B).

Pharmacodynamic

Information currently not available.

Mechanism of action

XTL001 is a combination of two high-affinity, fully human monoclonal antibodies that bind to distinct sites on the surface antigen of HBV to neutralize the virus and limit viral escape.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with XTL-001
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Abciximab
The risk or severity of adverse effects can be increased when Abciximab is combined with XTL-001.
Abituzumab
The risk or severity of adverse effects can be increased when XTL-001 is combined with Abituzumab.
Abrilumab
The risk or severity of adverse effects can be increased when XTL-001 is combined with Abrilumab.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with XTL-001.
Adecatumumab
The risk or severity of adverse effects can be increased when Adecatumumab is combined with XTL-001.
Aducanumab
The risk or severity of adverse effects can be increased when XTL-001 is combined with Aducanumab.
Afelimomab
The risk or severity of adverse effects can be increased when Afelimomab is combined with XTL-001.
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with XTL-001.
Alirocumab
The risk or severity of adverse effects can be increased when XTL-001 is combined with Alirocumab.
Amatuximab
The risk or severity of adverse effects can be increased when XTL-001 is combined with Amatuximab.
AMG 108
The risk or severity of adverse effects can be increased when XTL-001 is combined with AMG 108.
Anetumab ravtansine
The risk or severity of adverse effects can be increased when XTL-001 is combined with Anetumab ravtansine.
Anifrolumab
The risk or severity of adverse effects can be increased when XTL-001 is combined with Anifrolumab.
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when XTL-001 is combined with Anthrax immune globulin human.
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when XTL-001 is combined with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with XTL-001.
Apolizumab
The risk or severity of adverse effects can be increased when XTL-001 is combined with Apolizumab.
Apomab
The risk or severity of adverse effects can be increased when XTL-001 is combined with Apomab.
Ascrinvacumab
The risk or severity of adverse effects can be increased when XTL-001 is combined with Ascrinvacumab.
Asfotase alfa
The risk or severity of adverse effects can be increased when XTL-001 is combined with Asfotase alfa.
1 References
  1. 1 . Witherell G: XTL-001. XTL Pharmaceuticals. Curr Opin Investig Drugs. 2002 May;3(5):684-92.PubMed: 12090540